Position of the Transparency Council – Imfinzi (durvalumab)

At its meeting on 30 September 2024, the Transparency Council adopted position No. 102/2024 on the evaluation of the drug Imfinzi (durvalumab) under the drug program “Treatment of patients with lung cancer (ICD-10 C34) and pleural mesothelioma (ICD-10 C45)”

Publication of the position >>